Abstract:Objective To observe the clinical effects of intravitreal Ranibizumab injection (IVR)for the treatment of the macular edema due to branch retinal vein occlusion.Methods Sixty seven consecutive cases eyes of 67 of the macular edema due to branch retinal vein occlusion treated by IVR (10 mg/ml,0.05 ml) were retrospectively analyzed.All the cases were divided by the following two methods.According to the time between oncome of the macular edema and the first therapy,the patients were divided into 3 groups:group 1 of less than 1 week,group 2 of 1week-3 months and group 3 of over 3 months.And according to the treating regulation,the patients were divided into 2 groups:treatment on time group and treatment on demand group.The follow-up contents included the best corrected visual acuity (BCVA,LogMAR),1 mm diameter macular central retinal thickness (CRT) and fluorescence fundus angiography (FFA).The average follow-up period was (13.2 ± 1.3) months.Results When the group division according to the time between oncome of the macular edema and the first therapy,the BCVA of the patients in group 1 was 0.131 ±0.061 and CRT was (268 ±21) μm two months after the treatment.The BCVA was 0.086 ± 0.042 and CRT was (259 ± 19) μ m 12 months after the treatment.In group 2,the BCVA was 0.276 ± 0.112 and CRT was (321 ± 45) μm 2 months after the treatment and the BCVA was 0.292 ± 0.105 and CRT was (268 ±29) μm 12 months after the treatment.In group 3,the BCVA was 0.523 ±0.164 and CRT was (441 ± 67) μm two months after treatment,and the BCVA was 0.387 ± 0.142 and CRT was (281 ±24) μm 12 months after the treatment.When compared with the group 1,at every follow-up time point,the differences in the BCVAs were statistically significant between group 1 and group 2 (all P ＜0.01).The CRTs at 2,4,6 months after the treatment between group Ⅰ and group 3 had statistically significant differences (all P ＜0.01).When the group division according to the treatment regulation,12months after the treatment,the BCVA was 0.208 ±0.091 in the treatment on time group and was 0.387 ±0.184 in the treatment on demand group and the difference was statistically significant (t =4.35,P ＜0.01).Twelve months after the treatment,the CRT was (290 ±46) μm in the treatment on time group and was (311 ±51) μm in the treatment on demand group,and the difference was not statistically significant(t =0.98,P =0.56).Conclusion The curative effect of IVR for retinal edema due to branch retinal vein occlusion is obvious.Early and on time treatment could significantly improve the effects.

Effect of Vitreous Reflux after Intravitreal Aflibercept Injection for Macular Edema with Branch Retinal Vein Occlusion: A Real‐World Study

Subfoveal Choroidal Thickness and Treatment Outcomes of Intravitreal Aflibercept for Branch Retinal Vein Occlusion

Influence of Aflibercept on Choroidal Blood Flow and Thickness in Branch Retinal Vein Occlusion: A Six-Month Follow-Up Study

Vitreoretinal Interface Abnormalities in Patients With Retinal Vein Occlusion in a Tertiary Referral Center

Intravitreal Bevacizumab Treatment for Branch Retinal Vein Occlusion Accompanied by Macular Edema

Comparison of clinical efficacy of intravitreal ranibizumab with and without grid laser photocogagulation for macular edema secondary to branch retinal vein occlusion

Clinical study on intravitreous injection of Avastin for macular edema induced by central retinal vein occlusion

Bevacizumab Treatment for Acute Branch Retinal Vein Occlusion Accompanied by Subretinal Hemorrhage.

Relationship between Recurrence of Macular Edema Due to Branch Retinal Vein Occlusion and Changes in Choroidal Thickness

Visual Acuity and Retinal Thickness and Sensitivity after Intravitreal Ranibizumab Injection for Macular Edema in Branch Retinal Vein Occlusion

[Aflibercept in a real-world setting: the AURIGA study : 24-month results of the German cohort of treatment-naïve patients with macular edema following retinal vein occlusion receiving intravitreal aflibercept]

Comparison of subfoveal choroidal thickness in eyes with CRVO and BRVO

Changes in Ocular Blood Flow After Intravitreal Injection for Diabetic Macular Edema Between Aflibercept and Faricimab

Intravitreal conbercept for branch retinal vein occlusion induced macular edema: one initial injection versus three monthly injections

Effects of Intravitreal Ranibizumab Injection to Treat Macular Edema due to Central Retinal Vein Occlusion on Choroidal Findings and Functional-Morphological Parameters

Macular Edema Patterns and Response to Intravitreal Avastin Therapy in Branch Retinal Vein Occlusion

Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes

Effect of Intravitreal Injection of Anti VEGF Drugs on BCVA and Mferg Before and after Treatment for MCNV and ICNV

Intravitreal Injection of Ranibizumab for the Treatment of Macular Edema Due to Branch Retinal Vein Occlusion

Comparison of Choroidal Thickness, Foveal Avascular Zone, and Macular Capillary Density in Macular Edema Secondary to Branch Retinal Vein Occlusion Treated with Ranibizumab or Aflibercept—A Prospective Study

Intravitreal aflibercept for diabetic macular edema in real-world clinical practice in Japan: 24-month outcomes